CN114469882A - 一种右美沙芬奎尼丁口崩片及其应用 - Google Patents
一种右美沙芬奎尼丁口崩片及其应用 Download PDFInfo
- Publication number
- CN114469882A CN114469882A CN202210353658.5A CN202210353658A CN114469882A CN 114469882 A CN114469882 A CN 114469882A CN 202210353658 A CN202210353658 A CN 202210353658A CN 114469882 A CN114469882 A CN 114469882A
- Authority
- CN
- China
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- quinidine
- essence
- dextromethorphan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 title claims abstract description 114
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 70
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960001404 quinidine Drugs 0.000 title claims abstract description 57
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title claims abstract description 56
- 229960001985 dextromethorphan Drugs 0.000 title claims abstract description 56
- 235000019640 taste Nutrition 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 208000019505 Deglutition disease Diseases 0.000 claims abstract description 8
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 6
- 230000000873 masking effect Effects 0.000 claims description 38
- 239000000796 flavoring agent Substances 0.000 claims description 27
- 235000013355 food flavoring agent Nutrition 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 23
- 229960000913 crospovidone Drugs 0.000 claims description 23
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 23
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 23
- 235000002639 sodium chloride Nutrition 0.000 claims description 23
- 235000003599 food sweetener Nutrition 0.000 claims description 19
- 239000003765 sweetening agent Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000007884 disintegrant Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 229960001855 mannitol Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 108010011485 Aspartame Proteins 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 13
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 11
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 11
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000004376 Sucralose Substances 0.000 claims description 11
- 150000004677 hydrates Chemical class 0.000 claims description 11
- 235000019408 sucralose Nutrition 0.000 claims description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 238000002474 experimental method Methods 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000005715 Fructose Substances 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 229960002737 fructose Drugs 0.000 claims description 9
- 235000019202 steviosides Nutrition 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 8
- 229940013618 stevioside Drugs 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 7
- 240000002319 Citrus sinensis Species 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 238000013473 artificial intelligence Methods 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 208000026451 salivation Diseases 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 230000007278 cognition impairment Effects 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 7
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 7
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 229960004482 quinidine sulfate Drugs 0.000 description 6
- 210000002105 tongue Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960000948 quinine Drugs 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- MRUNQKQTAMUPRF-PUTLROBFSA-N nuedexta Chemical compound Br.OS(O)(=O)=O.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 MRUNQKQTAMUPRF-PUTLROBFSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical class NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 2
- -1 polygalacturonate Chemical compound 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical class O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- UZBODILCSLUHQR-JLMRSGIVSA-N zenvia Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 UZBODILCSLUHQR-JLMRSGIVSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
序号 | 矫味剂 | 序号 | 矫味剂 |
A1 | 蔗糖 | B8 | 牛奶香精 |
A2 | 三氯蔗糖 | B9 | 薄荷香精 |
A3 | 阿斯巴甜 | B10 | 甜橙香精 |
A4 | 甜菊糖苷 | B11 | 草莓香精 |
A5 | 甘露醇 | C12 | 柠檬酸 |
A6 | 山梨醇 | C13 | 乳酸 |
A7 | 果糖 | C14 | 碳酸钠 |
序号 | 样本组合 | 序号 | 样本组合 | 序号 | 样本组合 | 序号 | 样本组合 |
1 | A1B2C8 | 64 | A3B2C3 | 127 | A4B9C8 | 190 | A6B1C11 |
2 | A1B2C13 | 65 | A3B2C10 | 128 | A4B9C9 | 191 | A6B2C6 |
3 | A1B3C8 | 66 | A3B2C11 | 129 | A4B9C13 | 192 | A6B2C14 |
4 | A1B4C6 | 67 | A3B2C12 | 130 | A4B10C2 | 193 | A6B3C8 |
5 | A1B4C10 | 68 | A3B3C5 | 131 | A4B10C3 | 194 | A6B3C13 |
6 | A1B4C11 | 69 | A3B3C7 | 132 | A4B10C6 | 195 | A6B4C1 |
7 | A1B5C3 | 70 | A3B3C10 | 133 | A4B10C7 | 196 | A6B4C3 |
8 | A1B6C5 | 71 | A3B4C2 | 134 | A4B10C11 | 197 | A6B4C8 |
9 | A1B6C13 | 72 | A3B4C4 | 135 | A4B11C7 | 198 | A6B5C4 |
10 | A1B7C3 | 73 | A3B4C9 | 136 | A4B11C10 | 199 | A6B5C5 |
11 | A1B7C4 | 74 | A3B4C13 | 137 | A4B11C12 | 200 | A6B5C10 |
12 | A1B7C8 | 75 | A3B5C1 | 138 | A4B12C5 | 201 | A6B5C11 |
13 | A1B7C10 | 76 | A3B5C5 | 139 | A4B12C7 | 202 | A6B6C5 |
14 | A1B9C5 | 77 | A3B5C7 | 140 | A4B12C9 | 203 | A6B6C13 |
15 | A1B10C1 | 78 | A3B5C8 | 141 | A4B12C12 | 204 | A6B6C14 |
16 | A1B10C2 | 79 | A3B6C2 | 142 | A4B13C4 | 205 | A6B7C2 |
17 | A1B11C7 | 80 | A3B6C4 | 143 | A4B13C7 | 206 | A6B7C12 |
18 | A1B11C9 | 81 | A3B6C7 | 144 | A4B13C8 | 207 | A6B8C3 |
19 | A1B12C4 | 82 | A3B7C5 | 145 | A4B14C5 | 208 | A6B8C5 |
20 | A1B13C9 | 83 | A3B7C10 | 146 | A5B1C13 | 209 | A6B8C7 |
21 | A1B13C14 | 84 | A3B7C12 | 147 | A5B2C3 | 210 | A6B8C8 |
22 | A1B14C2 | 85 | A3B8C1 | 148 | A5B2C5 | 211 | A6B8C9 |
23 | A2B1C5 | 86 | A3B8C2 | 149 | A5B2C8 | 212 | A6B9C4 |
24 | A2B1C6 | 87 | A3B8C7 | 150 | A5B2C9 | 213 | A6B9C7 |
25 | A2B1C10 | 88 | A3B8C8 | 151 | A5B3C3 | 214 | A6B9C10 |
26 | A2B2C2 | 89 | A3B8C12 | 152 | A5B3C6 | 215 | A6B9C12 |
27 | A2B2C5 | 90 | A3B9C3 | 153 | A5B3C7 | 216 | A6B10C5 |
28 | A2B2C9 | 91 | A3B9C5 | 154 | A5B3C11 | 217 | A6B10C10 |
29 | A2B2C12 | 92 | A3B9C9 | 155 | A5B4C5 | 218 | A6B11C2 |
30 | A2B3C3 | 93 | A3B10C10 | 156 | A5B4C8 | 219 | A6B11C7 |
31 | A2B3C7 | 94 | A3B10C11 | 157 | A5B4C14 | 220 | A6B11C8 |
32 | A2B3C9 | 95 | A3B11C5 | 158 | A5B5C2 | 221 | A6B11C10 |
33 | A2B4C2 | 96 | A3B11C6 | 159 | A5B5C10 | 222 | A6B11C12 |
34 | A2B4C4 | 97 | A3B11C13 | 160 | A5B5C13 | 223 | A6B12C4 |
35 | A2B5C7 | 98 | A3B11C14 | 161 | A5B6C4 | 224 | A6B12C9 |
36 | A2B5C9 | 99 | A3B12C1 | 162 | A5B6C7 | 225 | A6B12C11 |
37 | A2B5C12 | 100 | A3B12C2 | 163 | A5B6C8 | 226 | A6B13C2 |
38 | A2B5C13 | 101 | A3B12C9 | 164 | A5B6C9 | 227 | A6B13C4 |
39 | A2B6C1 | 102 | A3B13C3 | 165 | A5B6C12 | 228 | A6B13C6 |
40 | A2B6C8 | 103 | A3B13C11 | 166 | A5B7C2 | 229 | A6B13C12 |
41 | A2B7C3 | 104 | A3B14C4 | 167 | A5B7C6 | 230 | A6B14C7 |
42 | A2B8C4 | 105 | A3B14C8 | 168 | A5B7C10 | 231 | A7B2C7 |
43 | A2B8C6 | 106 | A3B14C12 | 169 | A5B8C7 | 232 | A7B2C10 |
44 | A2B8C10 | 107 | A4B1C4 | 170 | A5B8C12 | 233 | A7B3C2 |
45 | A2B8C11 | 108 | A4B1C12 | 171 | A5B9C1 | 234 | A7B3C5 |
46 | A2B8C12 | 109 | A4B2C1 | 172 | A5B9C2 | 235 | A7B4C3 |
47 | A2B9C6 | 110 | A4B2C4 | 173 | A5B9C5 | 236 | A7B4C10 |
48 | A2B9C7 | 111 | A4B2C6 | 174 | A5B9C9 | 237 | A7B5C12 |
49 | A2B9C14 | 112 | A4B3C2 | 175 | A5B10C4 | 238 | A7B6C2 |
50 | A2B10C4 | 113 | A4B3C4 | 176 | A5B10C11 | 239 | A7B7C1 |
51 | A2B10C8 | 114 | A4B3C14 | 177 | A5B10C12 | 240 | A7B7C4 |
52 | A2B10C13 | 115 | A4B4C6 | 178 | A5B11C4 | 241 | A7B7C6 |
53 | A2B11C3 | 116 | A4B4C9 | 179 | A5B12C2 | 242 | A7B7C9 |
54 | A2B11C5 | 117 | A4B4C11 | 180 | A5B12C6 | 243 | A7B9C11 |
55 | A2B11C11 | 118 | A4B5C9 | 181 | A5B12C7 | 244 | A7B10C5 |
56 | A2B12C8 | 119 | A4B6C3 | 182 | A5B12C14 | 245 | A7B10C12 |
57 | A2B12C11 | 120 | A4B6C6 | 183 | A5B13C1 | 246 | A7B10C13 |
58 | A2B12C12 | 121 | A4B6C11 | 184 | A5B13C9 | 247 | A7B11C8 |
59 | A2B13C2 | 122 | A4B7C11 | 185 | A5B13C10 | 248 | A7B12C3 |
60 | A2B13C6 | 123 | A4B7C13 | 186 | A5B13C13 | 249 | A7B13C10 |
61 | A2B13C13 | 124 | A4B8C10 | 187 | A5B14C9 | 250 | A7B13C13 |
62 | A2B14C10 | 125 | A4B8C13 | 188 | A6B1C2 | 251 | A7B14C3 |
63 | A3B1C7 | 126 | A4B8C14 | 189 | A6B1C6 |
崩解剂 | 崩解时间(s) |
交联羧甲基纤维素钠+低取代羟丙纤维素 | 189 |
交联聚维酮 | 30 |
交联聚维酮+交联羧甲基纤维素钠 | 30 |
序号 | 交联聚维酮质量含量(%) | 崩解时间(s) |
1 | 28% | 29.0 |
2 | 22% | 32.6 |
3 | 16% | 48.0 |
5min(%) | 10min(%) | 30min(%) | |
氢溴酸右美沙芬 | 94 | 94 | 93 |
硫酸奎尼丁 | 95 | 95 | 94 |
Claims (26)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210353658.5A CN114469882B (zh) | 2022-04-06 | 2022-04-06 | 一种右美沙芬奎尼丁口崩片及其应用 |
PCT/CN2023/086493 WO2023193745A1 (zh) | 2022-04-06 | 2023-04-06 | 一种右美沙芬奎尼丁口崩片及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210353658.5A CN114469882B (zh) | 2022-04-06 | 2022-04-06 | 一种右美沙芬奎尼丁口崩片及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114469882A true CN114469882A (zh) | 2022-05-13 |
CN114469882B CN114469882B (zh) | 2023-10-20 |
Family
ID=81487491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210353658.5A Active CN114469882B (zh) | 2022-04-06 | 2022-04-06 | 一种右美沙芬奎尼丁口崩片及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114469882B (zh) |
WO (1) | WO2023193745A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114869888A (zh) * | 2022-05-14 | 2022-08-09 | 北京剂泰医药科技有限公司 | 一种树脂复合物组合物及其制备方法和应用 |
WO2023193745A1 (zh) * | 2022-04-06 | 2023-10-12 | 北京剂泰医药科技有限公司 | 一种右美沙芬奎尼丁口崩片及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720917A (zh) * | 2004-07-12 | 2006-01-18 | 河南大学 | 一种治疗咳嗽的口腔崩解片 |
CN101227894A (zh) * | 2005-07-22 | 2008-07-23 | 田边三菱制药株式会社 | 口腔速崩片 |
CN101732271A (zh) * | 2010-02-02 | 2010-06-16 | 江西中兴汉方药业有限公司 | 右美沙芬口崩片及其制备方法 |
CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
CN114469882B (zh) * | 2022-04-06 | 2023-10-20 | 北京剂泰医药科技有限公司 | 一种右美沙芬奎尼丁口崩片及其应用 |
-
2022
- 2022-04-06 CN CN202210353658.5A patent/CN114469882B/zh active Active
-
2023
- 2023-04-06 WO PCT/CN2023/086493 patent/WO2023193745A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720917A (zh) * | 2004-07-12 | 2006-01-18 | 河南大学 | 一种治疗咳嗽的口腔崩解片 |
CN101227894A (zh) * | 2005-07-22 | 2008-07-23 | 田边三菱制药株式会社 | 口腔速崩片 |
CN101732271A (zh) * | 2010-02-02 | 2010-06-16 | 江西中兴汉方药业有限公司 | 右美沙芬口崩片及其制备方法 |
CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
Non-Patent Citations (4)
Title |
---|
HARMIK SOHI ET AL.: ""Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》 * |
HARMIK SOHI ET AL.: ""Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》, vol. 30, no. 5, 25 May 2004 (2004-05-25), pages 429 - 448, XP055741215, DOI: 10.1081/DDC-120037477 * |
J.LENIK ET AL.: ""Evaluation of taste masking effect of diclofenac using sweeteners and cyclodextrin by a potentiometric electronic tongue"", 《JOURNAL OF ELECTROANALYTICAL CHEMISTRY》 * |
J.LENIK ET AL.: ""Evaluation of taste masking effect of diclofenac using sweeteners and cyclodextrin by a potentiometric electronic tongue"", 《JOURNAL OF ELECTROANALYTICAL CHEMISTRY》, vol. 780, 15 September 2016 (2016-09-15), pages 153 - 159, XP029780113, DOI: 10.1016/j.jelechem.2016.09.017 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023193745A1 (zh) * | 2022-04-06 | 2023-10-12 | 北京剂泰医药科技有限公司 | 一种右美沙芬奎尼丁口崩片及其应用 |
CN114869888A (zh) * | 2022-05-14 | 2022-08-09 | 北京剂泰医药科技有限公司 | 一种树脂复合物组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023193745A1 (zh) | 2023-10-12 |
CN114469882B (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114469882B (zh) | 一种右美沙芬奎尼丁口崩片及其应用 | |
JP3929618B2 (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 | |
WO2009022674A1 (en) | Medical composition containing rebamipide | |
BR112017024039B1 (pt) | Piroglutamato de vortioxetina | |
KR101744538B1 (ko) | 콜린 알포세레이트를 함유하는 수성 액상 제제 | |
US11331268B2 (en) | Taste masking product | |
KR20070118247A (ko) | 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제 | |
US20020006433A1 (en) | Pharmaceutical formulations | |
CN111617042A (zh) | 一种复合碳酸钙维生素d3无水吞服颗粒及其制备方法 | |
WO2011049122A1 (ja) | プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法 | |
CN114272233A (zh) | 一种奥司他韦组合物及其制备方法 | |
US20020173522A1 (en) | Pharmaceutical compositions comprising norastemizole | |
JP2011057655A (ja) | 口腔内崩壊錠 | |
CN112137971A (zh) | 一种甘磷酸胆碱的口腔崩解片及其制备方法 | |
CN113784711A (zh) | 包含格隆溴铵的口崩片剂和提高生物利用度的方法 | |
CN114569742B (zh) | 一种组合物及其制备方法和应用 | |
CN114522166B (zh) | 一种固体分散体组合物及其制备方法和应用 | |
Rouaz et al. | Excipients in the paediatric population: a review. Pharmaceutics 2021; 13: 387 | |
US20240009157A1 (en) | 3,5-diiodothyropropionic acid compositions and methods of use thereof | |
CN112546002B (zh) | 一种生物素口崩片及其制备方法 | |
Morel et al. | Selecting the food matrix with the highest masking power for delivering Recommendations for children intake | |
CN117797103A (zh) | 包装的右美沙芬奎尼丁口崩片 | |
Aslani et al. | Design, Formulation and Physicochemical Evaluation of Dimenhydrinate Orally Disintegrating Tablets | |
JP2006342188A (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 | |
Sasikumar | Formulation Development and Evaluation of Taste Masked Chewable Tablet of Sildenafil Citrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Dai Lixiang Inventor after: Qiu Shaojun Inventor after: Yin Le Inventor after: Chen Qiangxin Inventor after: Li Haiyan Inventor after: Chen Hongmin Inventor after: Lai Caida Inventor after: Wang Wenshou Inventor after: Huang Chuanren Inventor before: Dai Lixiang Inventor before: Qiu Shaojun Inventor before: Yin Le Inventor before: Chen Qiangxin Inventor before: Li Haiyan Inventor before: Chen Hongmin Inventor before: Lai Caida Inventor before: Wang Wenshou |
|
CB03 | Change of inventor or designer information |